Clinical Trial Update: A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib [Phase 1]

View source ↗

Summary

A completed Phase 1 study evaluated the bioequivalence of alternative formulations of Lapatinib in cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Lapatinib (Lapatinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms, Breast | Phase 1 | Status: COMPLETED